Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel dipeptidyl peptidase IV inhibitor shows promise in diabetes/obesity models

June 13, 2012

Phase I results encourage continued clinical evaluation of PEGylated C-peptide

June 13, 2012

Novel data reported on GKM-001 in diabetes and obesity

June 13, 2012

SIRT1 activation investigated in models of obesity

June 13, 2012

Protalix receives milestone payment for Elelyso approval

June 12, 2012

BioSante Pharmaceuticals plans new phase III LibiGel trials

June 12, 2012

Daiichi Sankyo presents new diacylglycerol O-acyltransferase inhibitors

June 12, 2012

U.S. researchers present new low-cost metabolic disease model

June 12, 2012

Researchers disclose lixisenatide data from GetGoal and other trials

June 12, 2012

Novel results disclosed on GLP-1 receptor agonist ZYOG-1

June 11, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...